Investment
Features
FeesSafety
Academy
More
Pluang+

SpaceX nears Starship's first orbital launch and Starlink V3 deployment, boosting investor optimism.

Market News
28 Sep 2026
Alex Lavoie
View Source
Bullish
SpaceX nears Starship's first orbital launch and Starlink V3 deployment, boosting investor optimism.

SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global internet capacity and marks a shift from Falcon 9 launches to Starship for satellite deployment. Investor enthusiasm is driven by Starship's potential to lower launch costs, support NASA missions, and enable future commercial space infrastructure, although some goals remain long-term and speculative. The stock has shown volatility reflecting excitement and uncertainties around execution and timelines.

SpaceX's recent developments with Starship and Starlink provide context for technology sector activity on Pluang. For readers following technology stocks, here is Pluang's market snapshot as of Sep 28, 2026 21:51 WIB: out of 150 priced US technology stocks, 15 rose and 133 fell. Notable movers include CRDO at USD 192.20 with a 1-day change of -8.90%, AXTI at USD 72.07 down 8.70%, and RBLX at USD 42.70 down 8.05%.

More News

Vertex Pharmaceuticals rises on strong cystic fibrosis sales and promising kidney drug trials, UBS hikes price target.

Vertex Pharmaceuticals rises on strong cystic fibrosis sales and promising kidney drug trials, UBS hikes price target.

Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....

Analyst Insights
Bullish
31 minutes ago
Accenture's stock jumps 37.6% on booming AI demand and strong financials ahead of Q4 earnings.

Accenture's stock jumps 37.6% on booming AI demand and strong financials ahead of Q4 earnings.

Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...

Analyst Insights
Bullish
1 hour ago
10x Genomics gets Buy rating despite insider selling and valuation concerns.

10x Genomics gets Buy rating despite insider selling and valuation concerns.

Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...

Analyst Insights
Neutral
2 hours ago
Morgan Stanley upgrades Cullen/Frost Bankers with strong institutional buying and a $201 price target.

Morgan Stanley upgrades Cullen/Frost Bankers with strong institutional buying and a $201 price target.

Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...

Analyst Insights
Bullish
2 hours ago
Strong Q1 earnings growth expected for AAR Corp. driven by aviation parts demand

Strong Q1 earnings growth expected for AAR Corp. driven by aviation parts demand

AAR Corp. is set to report strong Q1 earnings with analysts expecting EPS of around $1.29 and revenue near $882 million, up significantly from last year. The company benefits from robust organic growth in aviation parts distribution, supporting healt...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App